PURPOSE: To compare the outcomes associated with modifications in three consecutive protocols employed by the Italian Co-Operative Group for Neuroblastoma (ICGNB) in disseminated neuroblastoma. PATIENTS AND METHODS: Between January 1985 and November 1997, a total of 359 children aged 1 to 15 years with newly diagnosed stage 4 neuroblastoma were enrolled in three consecutive protocols. Compared with ICGNB-85, the ICGNB-89 protocol contained two more chemotherapy cycles, and some drugs were given at greater doses, whereas in the ICGNB-92 protocol, the induction phase included a chelating agent, and individual cycles contained four drugs instead of two. RESULTS: A total of 330 of 359 evaluable children were included in this analysis; 106 children were treated with ICGNB-85, 65 children were treated with ICGNB-89, and 159 children were treated with ICGNB-92 protocols. Radical resection of primary tumor was carried out in 59.4%, 50.8%, and 57.9% of the patients, respectively. Major tumor response after induction therapy was achieved in 66.7%, 69.2%, and 68.6% of the patients, respectively. A total of 218 of 232 patients received consolidation therapy consisting of conventional chemotherapy in 65 patients and of high-dose chemotherapy in 153 patients. Disease recurrence or progression occurred in 82.1%, 69.2%, and 74.8% of the patients, respectively. Therapy-related deaths occurred in 1.9%, 12.3%, and 6.9% of the patients, respectively. Five-year overall survival (OS) for the three studies was 26%, 23%, and 28%, and event-free survival (EFS) was 19%, 17%, and 17%, respectively. CONCLUSION: The therapeutic modifications adopted in the ICGNB-89 and ICGNB-92 protocols were not associated with a significant improvement in response rate or in the 5-year OS and EFS as compared with the ICGNB-85 protocol. Attempts at intensifying chemotherapy were associated with greater toxicity.
PURPOSE: To compare the outcomes associated with modifications in three consecutive protocols employed by the Italian Co-Operative Group for Neuroblastoma (ICGNB) in disseminated neuroblastoma. PATIENTS AND METHODS: Between January 1985 and November 1997, a total of 359 children aged 1 to 15 years with newly diagnosed stage 4 neuroblastoma were enrolled in three consecutive protocols. Compared with ICGNB-85, the ICGNB-89 protocol contained two more chemotherapy cycles, and some drugs were given at greater doses, whereas in the ICGNB-92 protocol, the induction phase included a chelating agent, and individual cycles contained four drugs instead of two. RESULTS: A total of 330 of 359 evaluable children were included in this analysis; 106 children were treated with ICGNB-85, 65 children were treated with ICGNB-89, and 159 children were treated with ICGNB-92 protocols. Radical resection of primary tumor was carried out in 59.4%, 50.8%, and 57.9% of the patients, respectively. Major tumor response after induction therapy was achieved in 66.7%, 69.2%, and 68.6% of the patients, respectively. A total of 218 of 232 patients received consolidation therapy consisting of conventional chemotherapy in 65 patients and of high-dose chemotherapy in 153 patients. Disease recurrence or progression occurred in 82.1%, 69.2%, and 74.8% of the patients, respectively. Therapy-related deaths occurred in 1.9%, 12.3%, and 6.9% of the patients, respectively. Five-year overall survival (OS) for the three studies was 26%, 23%, and 28%, and event-free survival (EFS) was 19%, 17%, and 17%, respectively. CONCLUSION: The therapeutic modifications adopted in the ICGNB-89 and ICGNB-92 protocols were not associated with a significant improvement in response rate or in the 5-year OS and EFS as compared with the ICGNB-85 protocol. Attempts at intensifying chemotherapy were associated with greater toxicity.
Authors: Jared R Robbins; Matthew J Krasin; Atmaram S Pai Panandiker; Amy Watkins; Jianrong Wu; Victor M Santana; Wayne L Furman; Andrew M Davidoff; Lisa M McGregor Journal: J Pediatr Surg Date: 2010-04 Impact factor: 2.545
Authors: Patrick M Long; Holly M Stradecki; Jane E Minturn; Umadevi V Wesley; Diane M Jaworski Journal: Int J Cancer Date: 2011-04-01 Impact factor: 7.396
Authors: Brian H Kushner; Irina Ostrovnaya; Irene Y Cheung; Deborah Kuk; Kim Kramer; Shakeel Modak; Karima Yataghene; N K Cheung Journal: Oncoimmunology Date: 2015-05-22 Impact factor: 8.110
Authors: Robert J Rounbehler; Weimin Li; Mark A Hall; Chunying Yang; Mohammad Fallahi; John L Cleveland Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: Roberta Vitali; Camillo Mancini; Vincenzo Cesi; Barbara Tanno; Marta Piscitelli; Mariateresa Mancuso; Fabiola Sesti; Emanuela Pasquali; Bruno Calabretta; Carlo Dominici; Giuseppe Raschellà Journal: Int J Cancer Date: 2009-12-01 Impact factor: 7.396
Authors: Roberta Vitali; Camillo Mancini; Vincenzo Cesi; Barbara Tanno; Mariateresa Mancuso; Gianluca Bossi; Ying Zhang; Robert V Martinez; Bruno Calabretta; Carlo Dominici; Giuseppe Raschellà Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: Peter E Zage; Morris Kletzel; Kevin Murray; Robert Marcus; Robert Castleberry; Yang Zhang; Wendy B London; Cynthia Kretschmar Journal: Pediatr Blood Cancer Date: 2008-12 Impact factor: 3.167
Authors: I Cellai; G Petrangolini; M Tortoreto; G Pratesi; P Luciani; C Deledda; S Benvenuti; C Ricordati; S Gelmini; E Ceni; A Galli; M Balzi; P Faraoni; M Serio; A Peri Journal: Br J Cancer Date: 2010-01-12 Impact factor: 7.640